JCI The Journal of Clinical Investigation

The extrathyroidal conversion rate of thyroxine to triiodothyronine in normal man

Constance S. Pittman, ..., Joseph B. Chambers Jr., Virginia H. Read

J Clin Invest. 1971;50(6):1187-1196. https://doi.org/10.1172/JCI106596.

Research Article

Eight normal subjects were administered tracer amounts of a¹⁴C-labeled thyroxine, L-[tyrosyl-¹⁴C] T₄, by multiple injections. Then serial blood samples were collected for isolation of the thyroxine, triiodothyronine, and tetraiodothyroacetic acid fractions by a combination of column and paper chromatographies. The chromatographic artifacts were corrected by adding to the sera a purified ³H-labeled thyroxine, D,L-[α , β -³H] T₄ immediately after the separation of sera from blood. 1-2% of the serum ¹⁴C radioactivity was observed in the triiodothyronine fraction and 2-4% of the serum ¹⁴C radioactivity was observed in the triiodothyronine fraction and 2-4% of the serum ¹⁴C radioactivity was observed in the tetraiodothyroacetic acid fraction. Complete kinetic studies of thyroxine and triiodothyronine were compared in the same individual in four of the subjects. The extrathyroidal conversion rates of thyroxine to triiodothyronine were calculated from data obtained during both the injection and the postinjection periods as functions of the ¹⁴C-labeled thyroxine and triiodothyronine remaining in the body at time t and their fractional turnover rates. The average daily rate of the extrathyroidal conversion of thyroxine to triiodothyronine was 4% of the extrathyroidal thyroxine pool or 33% of the total thyroxine production. The amount of triiodothyronine generated by this pathway (22 µg/day) was found to contribute 31% of the extrathyroidal triiodothyronine pool or 41% of the daily triiodothyronine production. This pathway is a major source of triiodothyronine production. The extrathyroidal conversions of thyroxine to triiodothyronine and tetraiodothyronine [...]



Find the latest version:

https://jci.me/106596/pdf

The Extrathyroidal Conversion Rate of Thyroxine to Triiodothyronine in Normal Man

CONSTANCE S. PITTMAN, JOSEPH B. CHAMBERS, JR., and VIRGINIA H. READ

From the Department of Medicine, University of Alabama Medical Center, Birmingham, Alabama 35233

ABSTRACT Eight normal subjects were administered tracer amounts of a ¹⁴C-labeled thyroxine, L-[tyrosyl-¹⁴C7 T₄, by multiple injections. Then serial blood samples were collected for isolation of the thyroxine, triiodothyronine, and tetraiodothyroacetic acid fractions by a combination of column and paper chromatographies. The chromatographic artifacts were corrected by adding to the sera a purified ³H-labeled thyroxine, D,L- $[\alpha,\beta-^{3}H]$ T₄ immediately after the separation of sera from blood. 1-2% of the serum ¹⁴C radioactivity was observed in the triiodothyronine fraction and 2-4% of the serum ¹⁴C radioactivity was observed in the tetraiodothyroacetic acid fraction. Complete kinetic studies of thyroxine and triiodothyronine were compared in the same individual in four of the subjects. The extrathyroidal conversion rates of thyroxine to triiodothyronine were calculated from data obtained during both the injection and the postinjection periods as functions of the ¹⁴C-labeled thyroxine and triiodothyronine remaining in the body at time t and their fractional turnover rates. The average daily rate of the extrathyroidal conversion of thyroxine to triiodothyronine was 4% of the extra hyroidal thyroxine pool or 33%of the total thyroxine production. The amount of triiodothyronine generated by this pathway (22 μ g/day) was found to contribute 31% of the extrathyroidal triiodothyronine pool or 41% of the daily triiodothyronine production. This pathway is a major source of triiodothyronine production. The extrathyroidal conversions of thyroxine to triiodothyronine and tetraiodothyroacetic acid are major metabolic pathways of thyroxine in normal man.

INTRODUCTION

Since the presence of triiodothyronine $(T_3)^1$ in human plasma was first reported in 1952, the source of this circulating hormone has never been clearly defined (1). It is known that some triiodothyronine is released by the thyroid gland into the blood. At least in the lower animals, the concentration of triiodothyronine is higher in the venous effluent than the arterial blood of the thyroid (2, 3). The possibility of extrathyroidal deiodination of thyroxine (T₄) to triiodothyronine had also been entertained by many investigators. However, in the early human studies, the attempts to identify ¹³¹I-labeled T₃ following a single injection of ¹³¹I-labeled T₄ only yielded equivocal results (4, 5). Volpert, Greenberg, and Werner found triiodothyronine in both normal pituitary and transplanted pituitary tumor of mice after the injection of ¹³¹I-labeled thyroxine (6). Albright, Larson, and Tust detected triiodothyronine after incubating ¹³¹I-labeled thyroxine with rat kidney tissue (7). While there were such exceptions, most animal studies by either in vivo or in vitro techniques also failed to substantiate deiodination of T_4 as a significant pathway that gives rise to circulating T_3 (6-8). More recently Braverman, Ingbar, and Sterling analyzed the total serum T₄ and T₃ in hypothyroid patients maintained on pharmacological doses of L-thyroxine (9). The T₃: T₄ ratios in their sera were found to be higher than the ratio in the ingested L-thyroxine preparation. These same investigators also administered multiple injections of ¹²⁵I-labeled thyroxine to two athyreotic patients. Approximately 1-2% of the serum radioactivity was found to be in the triiodothyronine fraction and twice that in the tetraiodothyroacetic acid (Tetrac) fraction. This study strongly suggested the presence of extrathyroidal conversion of T_4 to T_3 in man. In a study by Pittman, Nakafuji, and Read in normal men, ¹⁴C-

This work was presented in part at the American Society for Clinical Investigation, 3 May 1970 in Atlantic City, N. J., and at the 6th International Thyroid Conference, 22 June 1970 in Vienna, Austria.

Dr. Read is a special postdoctoral fellowship awardee granted by the U. S. Public Health Service.

Received for publication 19 August 1970 and in revised form 28 January 1971.

¹ Abbreviations used in this paper: K, fractional turnoverrate; T_3 , triiodothyronine; T_4 , thyroxine; Tetrac, tetraiodothyroacetic acid; V_d , volume of distribution.

labeled T_3 and Tetrac were also regularly observed after repeated intravenous injections of ¹⁴C-labeled T_4 (10). The present report contains our measurement of the rate of this extrathyroidal conversion of T_4 to T_3 in similarly prepared normal subjests. T_4 and T_3 kinetic studies were compared in the same individuals in order to define the biological significance of the pathway of extrathyroidal conversion of T_4 to T_3 in man.

METHODS

Materials. Two types of radiothyroxines were used in the studies. One radiothyroxine was labeled with ¹⁴C in the nonphenolic ring and the alanine side chain, L-[tyrosyl-14C] T₄. It was synthesized by the method of Shiba and Cahnmann by Amersham-Searle Corp., Arlington Heights, Ill. and it had a specific activity of 135 mCi/mmole (11). The L-[tyrosyl-14C] T_4 was used to calculate the T_4 to T_3 conversion rates. The other radiothyroxine was labeled with ³H in the alpha and beta carbons of the side chain, D,L- $[\alpha,\beta^{-3}H]$ T₄, with a specific activity of 125 mCi/mmole. The D,L- $[\alpha,\beta^{-3}H]$ T₄ was synthesized by Dr. J. Nunez with the method of Nunez, Jacquemin, and Roche (12). The sample contained primarily L-thyroxine but it was not free of some D-thyroxine. The D,L- $\left[\alpha,\beta-^{3}H\right]$ T₄ was used only as a methodological control in the correction for artifactual T₄ deiodination and for the calculation of T₄ recoveries during our chromatographic manipulations. In addition, a ¹³¹I-labeled triiodothyronine, L-[3'-¹³¹I] T₃ was purchased from the Abbott Laboratories, North Chicago, Ill., specific activity 1.79×10^4 mCi/mmole. The purity of radioactive T₄ and T₃ was 98% or greater before use. They were prepared for injection in a sterile solution of 1% ethanol, 0.9%scdium chloride, and 1% human albumin as described previously (13). Every thyroxine dose was chromatographed in at least two solvent systems and the presence of triiodothyronine was assayed directly in a liquid scintillation counter as described below. Two D,L-[α , β -³H] T₄ standards were prepared and they contained 0.52 and 0.50% of 3H-labeled triiodothyronine. Five injection doses of D,L-[α , β -³H] T₄ were prepared. The range of 3H-labeled triiodothyronine contained in these preparations was 0.46-0.81%. Seven injection doses of L-[tyrosyl-14C] T₄ were prepared. The range of ¹⁴C-labeled triiodothyronine detected in these doses was 0.59-0.82%

Subjects. Studies were carried out in eight young, healthy male subjects free of any past history or family history of thyroid disorder. The details of their clinical information are

listed in Table I. Throughout the experiment the subjects were housed in the Clinical Research Center of the University of Alabama Medical Center. Each subject was given daily intravenous injections of L-[tyrosyl-14C] T₄ for 10 days. The total T4 dose was 8-11 µg per day. Throughout the experiment serial blood samples were taken. In addition, 24-hr urines and feces were collected for radioisotope recoveries. On the 20th day of experiment, an intravenous injection of D,L- $\left[\alpha,\beta-^{3}H\right]T_{4}$ was given to four of the subjects (97.4 μ g). The D,L-[α , β -³H] T₄ experiment was carried out to determine the rate at which the extrathyroidal conversion of T_4 to T_3 reaches an equilibrium. During the 24th-27th days of experiment these same four subjects were given Lugol's solution orally, five drops, t.i.d. (three times a day). They were given 200 μ Ci of L-[3'-131]] T_a intravenously in one injection for the kinetic studies of T₃. During the studies with D,L-[α,β -³H] T₄ and L-[3'-¹³¹I] T₃, the collections of blood, urine, and feces were made every 12 hr.

Laboratory procedures. Sera were separated immediately after blood collection. Into those samples which did not contain previously injected D,L- $[\alpha,\beta^{-3}H]$ T₄, a small amount of purified D,L- $[\alpha,\beta^{-3}H]$ T₄ was added as a control for T₄ recovery and for artifactual T₃ production. The amounts of ³H-labeled T₃ found at the end of all chromatographic manipulations were used to correct for the in vitro T₄ to T₃ conversion. For samples which contained previously injected D,L- $[\alpha,\beta^{-3}H]$ T₄, the ³Hlabeled T₃ found in the blood 10 min after the injection of D,L- $[\alpha,\beta^{-3}H]$ T₄ was used for similar correction.

The T₄, T₃, and Tetrac fractions were isolated from serum by a combination of column and filter-paper chromatographies (14). The serum samples were deproteinized on a resin column, Dowex AG, W-X2 (Dow Chemical Co., Midland, Mich.) (H⁺ form). After washing the column with water and 0.15 M ammonium acetate, the T_4 , T_3 , and Tetrac fractions were eluted with 7.4 N ammonium hydroxide. The eluent was condensed by lyophilization and applied on a No. 3 Whatman paper. The two-dimensional chromatogram was developed in a solvent of hexane, tertiary amyl alcohol, and 2 N ammonia (1:5:6) in a descending system for the first direction and then in an ascending system in the second direction. A small amount of carrier T_3 (5 μ g/ μ l) was added into the condensed eluent to facilitate visualization of the T3 area on the paper chromatogram under ultraviolet light. T4 was present in adequate amount to be detected by ultraviolet light without the use of carrier T_4 . The T_4 , T_3 , and Tetrac areas were cut out in 2×0.5 cm strips. The mean T₄ recovery was 54.8% with a range of 45.8-62.8%. For each run of serum, a tracer amount of a purified L-[3'-¹³¹I] T₃ was added to a portion of the same sample and the paired portions were carried through the entire

Patients, age, and sex		Thyroidal uptake of ¹³¹ I	Total serum T4	Total serum T3	T4: T3 ratios	L-[tyrosyl-14C] T4 inj.	
yr			% 24 hr ⁻¹	µg/100 ml	ng/100 ml	·····	dpm × 10 ⁶ day ⁻¹
J. McD.	22	Μ	17.8	8.0	230	35	3.090
D. D.	21	Μ	7.8	4.5	140	32	7.713
D. V.	21	Μ	32.7	6.5	165	39	4.480
B. H.	23	Μ	36.1	7.0	160	44	4.480
J. Mu.	22	Μ	20.2	6.5	210	31	4.452
D. G.	22	Μ	16.7	5.5	190	29	4.279
J. S.	22	Μ	17.5	4.2			
J. Ma.	23	Μ	22.8	4.9			

TABLE I Clinical Information of the Subjects

chromatographic procedure simultaneously in a parallel fashion. The T₃ recovery was calculated from the recovered L- $[3'^{131}]$ T₃. The over-all T₃ recovery by this method was 17.2–31.8%. In the present study some serum samples were controlled by D,L- $[\alpha,\beta^{-3}H]$ T₄. Both the trace amounts of ³H-T₄ contaminant and the trace amounts of ³H-labeled T₃ which was produced by the in vitro deiodination of D,L- $[\alpha,\beta^{-3}H]$ T₄, contributed ³H activity to the T₃ zone on paper chromatograms. The per cent of ³H radioactivity detected in the T₃ zone was assumed to be the same as the percent of ¹⁴C radioactivity contributed by the same artifacts which were corrected for in our calculation of ¹⁴C-T₃. The over-all recovery of thyroxine calculated from the D,L- $[\alpha,\beta^{-3}H]$ T₄ standard was 7.9–19.0%.

The ¹⁴C and ³H activities were assayed in a dioxane scintillator (1% PPO, 0.05% POPOP, and 5% naphthalene) with a liquid scintillation counter (Nuclear-Chicago Corporation, Des Plaines, Ill.). The gamma radioactivity of ¹³¹I was assayed in a well scintillation counter (Nuclear-Chicago Corporation, Des Plaines, Ill.).

The half-times of T_4 were obtained from the ¹⁴C data 24 hr after the last injection of L-[tyrosyl-¹⁴C] T_4 . The disappearance of ¹⁴C radioactivity in blood was followed for 9–12 days during which time five to seven samples were collected from each subject for the calculation of half-times.

In the study of T_3 kinetics, the ¹³¹I activities in both the native serum and the protein precipitate were assayed. The latter was used in our calculation. The serum was precipitated by the following procedure. To 1.0 ml of serum was first added 25 µg/ml of carrier sodium iodide and enough propyl-thiouracil to make a 10^{-5} M solution, followed by 1.0 ml of cold 20% trichloroacetic acid. The resulting precipitate was washed three times with cold 5% trichloroacetic acid.

The measurements of the total serum T_4 and T_3 were carried out by the Boston Medical Laboratory, Waltham, Mass. The serum T_4 was measured by a modification of the method of Murphy and Pattee (15). The serum T_3 was measured according to a modified method of Sterling, Bellabarba, Newman, and Brenner (14).

Calculation. The serum radioactivity was plotted as a function of time. The half-time (t_2) of T_4 or T_3 was obtained from the respective linear regression. The fractional turnoverrate (K) and the zero time volume of distribution (V_d) were calculated by a method similar to that described by Ingbar and Freinkel (16). The total body pool was derived from the product of the serum concentration and the volume of distribution. The daily production rate (or disposal rate) was calculated from the product of the serum concentration, the volume of distribution, and the fractional turnover-rate of T_4 or T_3 . In the study of T_3 kinetics, the problem of iodoproteins that arises as a product of T_3 degradation was avoided by using only the data collected between 24–72 hr after an injection of L-[3'-1¹⁰I] T₃ (17).

The kinetics in the extra hyroidal conversion of T_4 to T_3 are calculated by the following:

- A = the daily injection dose of radiothyroxin in dpm.
- $[T_4]$ = the amount of injected L-[tyrosyl-¹⁴C] T₄ in the body in dpm at time t.
- $[T_3]$ = the amount of L-[tyrosyl-¹⁴C] T_3 in the body in dpm at time t.
 - K_4 = the fractional turnover-rate of thyroxine, per day.
 - K_3 = the fractional turnover-rate of triiodothyronine, per day.
 - λ = the extrathyroidal conversion rate of thyroxine to triiodothyronine per day.
 - t^* = the time of last injection of radiothyroxin in days.
 - t = the time of blood sample collection in days.

In this calculation the following assumptions are made:

(a) K_3, K_4, and λ are independent of both time and the amount of T_3 and T_4 present.

(b) λ/K_4 is close to zero.

(c) A units of labeled T_4 are administered daily for t* days.

$$\frac{\mathrm{d}[\mathrm{T}_4]}{\mathrm{d}t} = \mathrm{A} - \mathrm{K}_4[\mathrm{T}_4]. \tag{1}$$

For $A \neq 0$, the solution of (1) is

$$[T_4] = \frac{A}{K_4}(1 - e^{-K_4 t}).$$
 (2)

For A = 0, i.e. for $t > t^*$, the solution to (1) is

$$[T_4] = Ce^{-K_4 t} \tag{3}$$

where C must be evaluated from the initial conditions. In this case, the initial conditions are that at $t = t^* [T_4]$ is given by, from (2), $A(1 - e^{-K_4 t^*})/K_4$. Using this, equation (3) becomes

$$[T_4] = \frac{A}{K_4} (1 - e^{-K_4 t^*}) e^{K_4 (t^* - t)}.$$
 (4)

The extrathyroidal conversion of T₄ to T₃ can be described by

$$\frac{\mathrm{d}[\mathrm{T}_3]}{\mathrm{d}t} = \lambda[\mathrm{T}_4] - \mathrm{K}_3[\mathrm{T}_3]. \tag{5}$$

As was the case for $[T_4]$, the solution of (5) will have one of two forms, depending on whether or not A = 0. For $A \neq 0$, the initial condition is that $[T_3] = 0$ for t = 0, and the solution to (5) is

$$\begin{bmatrix} T_{3} \end{bmatrix} = \frac{\lambda A}{K_{3}K_{4}(K_{3} - K_{4})} \\ \times \begin{bmatrix} K_{3}(1 - e^{-K_{4}t}) - K_{4}(1 - e^{-K_{3}t}) \end{bmatrix}.$$
(6)

For A = 0, the initial condition is that, at $t = t^*$, $[T_3]$ is given by (6), with t* replacing t. Using this, the solution to (5) becomes

$$\begin{bmatrix} T_3 \end{bmatrix} = \frac{\lambda A}{K_3 K_4 (K_3 - K_4)} \begin{bmatrix} K_3 (1 - e^{-K_4 t^*}) e^{-K_4 (t - t^*)} \\ - K_4 (1 - e^{-K_3 t^*}) e^{-K_3 (t - t^*)} \end{bmatrix}.$$
(7)

For $t \leq t^*$, the extra thyroidal conversion rate, λ , can be found, after dividing (6) by (2), as

$$\lambda = \frac{K_{3}(K_{3} - K_{4})}{K_{3} - K_{4} \frac{1 - e^{-K_{4}t}}{1 - e^{-K_{4}t}} \begin{bmatrix} T_{3} \end{bmatrix}}$$
(8)

For $t > t^*$, λ can be found by dividing (7) by (4).

$$\lambda = \frac{K_{3}(K_{3} - K_{4})}{K_{3} - K_{4} \left(\frac{e^{K_{3}t^{*}} - 1}{e^{K_{4}t^{*}} - 1}\right) e^{-(K_{3} - K_{3})t}} \begin{bmatrix} T_{3} \\ T_{4} \end{bmatrix}}$$
(9)

RESULTS

The clinical information of our subjects are summarized in Table I. Our subjects were given 10 daily injections of L-[tyrosyl-¹⁴C] T₄. During the entire 20 days of study the average ¹⁴C recovery from urine was 37.6% of the injected dose with a range of 27.7-50.3%. The fecal collections from five of the eight subjects were complete. The average recovery of ¹⁴C from feces was 13.0% of the injected dose with a range of 9.2-14.4%. Fig. 1 shows the cumulative and daily recoveries of ¹⁴C

Thyroxine Metabolism in Man 1189




FIGURE 1 ¹⁴C recoveries from urine. Each subject was given L-[tyrosyl-¹⁴C] T₄ 8–11 μ g/day intravenously for 10 days.


from urine of subjects J. S. and D. D. This pattern of urinary recovery was typical of the remaining subjects of the group.

In all serum samples studied, ¹⁴C radioactivity was consistently found in the T₄, T₃, and Tetrac fractions. The ¹⁴C-labeled Tetrac was always found in equal or slightly larger amounts than the ¹⁴C-labeled T₃. The ¹⁴C radioactivity in the T₃ fraction represented 1.56 $\pm 0.50\%$ of the total ¹⁴C radioactivity in serum. The recovery of Tetrac was not measured. Of the total radioactivity applied to the chromatogram paper, 0.4–4.3% was found in the Tetrac fraction.

In all the subjects studied trace amounts of D,L- $[\alpha,\beta^{-3}H]$ T₄ were added to sera either in vitro or in vivo as a control. The need of such a control is shown in Fig. 2. Subject J. McD. had previously been equilibrated with L-[tyrosyl-14C] T₄. Then he was given an injection of D,L- $[\alpha,\beta^{-3}H]$ T₄. A serum sample drawn 10 min after the injection of D,L-[α,β -³H] T₄ showed 0.27% ³H activity in the T₃ fraction which was likely due to the D,L-[α,β -³H] T₃ in the injection dose, the D,L-[α,β -³H] T_4 remaining in the T_3 fraction and some D,L- $\lceil \alpha, \beta^{-3}H \rceil$ T₃ formed artifactually in vitro. The serum study of a similarly prepared subject, B. H., is shown in Fig. 3 in which the ³H/¹⁴C ratios of the deproteinized serum, the T_4 and T_3 fractions are plotted as functions of time. The ³H/¹⁴C ratios of the deproteinized serum and of the T4 fraction remained nearly constant after the initial equilibration of D,L- $[\alpha,\beta^{-3}H]$ T₄ with the body pool of

T₄. The ³H/¹⁴C ratio in the T₃ fraction rose and did not reach a plateau until 48 hr after the injection of D,L- $[\alpha,\beta-^{3}H]$ T₄. If the ³H activity in the T₃ fraction was due to T₃ contamination in the D,L- $[\alpha,\beta-^{3}H]$ T₄ dose and chromatographic artifacts, the ³H/¹⁴C ratio in the T₃ fraction should have fallen or remained con-

Patient J. Mc·D.
Serum
10 minutes postinjection of D,
$$L - \left[\alpha \beta - {}^{3}H\right] T_{4}$$



FIGURES 2 and 3 The subjects had been equilibrated with L-[tyrosyl-14C] T₄ previously and were then given one injection of D,L-[α,β -3H] T₄, intravenously, 97.4 μ g. Serial blood samples were collected. The two-dimensional paper chromatograms of the deproteinized sera were developed in a solvent system of hexane:tertiary amyl alcohol:2 N ammonium hydroxide in both directions. The T₄ and T₈ areas were cut out and assayed for ¹⁴C and ³H radioactivities.

1190 C. S. Pittman, J. B. Chambers, Jr., and V. H. Read

stant. Therefore, the radioactivity found in the T_3 fraction was contributed primarily by the in vivo conversion of radioactive T_4 to T_3 in addition to the artifacts mentioned before.

It is assumed that during chromatographic manipulations the ³H and ¹⁴C-labeled thyroxines contributed similar fractions of their respective radioactivities to the T₃ area on paper chromatograms due to T₄ remaining in the T_3 fraction and due to T_4 to T_3 conversion in vitro. Therefore, the fraction of ³H activity was used to correct for the contribution of ¹⁴C due to these artifacts in the T_3 area. When this value was equal to or less than the labeled T_3 contaminant in the original T_4 injection dose, no net correction was made. In actuality, no net correction was necessary in most of our calculations of $[T_3]$. For example: to 10 ml serum of J. Mu. trace amounts of ¹³¹I-labeled T₃ standard were added. To another 10 ml serum of J. Mu. trace amounts of a 3 H-labeled T₄ standard were added. After all the chromatographic manipulations, 62 dpm of ³H was recovered from the T₃ area of the final paper chromatogram or 0.48% of the total ³H activity applied to the paper. From the same T₃ area, 55 dpm of ¹⁴C activity was recovered. The over-all T₃ recovery calculated from the 131 I T₃ standard was 17.7%. Since the per cent of ³H-labeled T₃ contaminant in the original injection dose of ${}^{3}\text{H-T}_{4}$ was approximately the same (0.50%) as that recovered in the T₃ area, no correction for artifacts was made. Therefore, the serum concentration of ¹⁴Clabeled $T_3 = 5.5 \text{ dpm} \div 17.7 \times 100 = 31 \text{ dpm ml}^{-1}$. The chromatographic data are summarized in Table II.

From sera collected during L-[tyrosyl-¹⁴C] T₄ injections the [T₄] value or the amount of L-[tyrosyl-¹⁴C] T₄ remaining in the body at time t was calculated from equation (2), $[T_4] = A/K_4(1 - e^{-K_4 t})$. The extrathyroidal conversion rate, λ , was calculated from equation (8), $\lambda = (K_3[K_3 - K_4])/(K_3 - K_4[1 - e^{-K_4 t}])/[1 - e^{-K_4 t}])/[T_3]/[T_4]$. From sera collected after all 10 injections of L-[tyrosyl-¹⁴C] T₄, [T₄] was calculated from equation (4), $[T_4] = A/K_4(1 - e^{-K_4 t^*})e^{K_4(t^*-t)}$, and λ from equation (9),

$$\lambda = \frac{K_{3}(K_{3} - K_{4})}{K_{3} - K_{4} \left(\frac{e^{K_{3}t^{*}} - 1}{e^{K_{4}t^{*}} - 1}\right) e^{-(K_{3} - K_{4})t}} \frac{[T_{3}]}{[T_{4}]}.$$

However, for interest of comparison, $[T_4]$ values calculated from two other methods are listed in Table III along with those calculated from equations (2) and (4). In one of the methods the serum concentration of L-[tyrosyl-¹⁴C] T₄ was obtained from the ¹⁴C activity found in the T₄ area of the final paper chromatogram and the over-all T₄ recovery. In turn, $[T_4]$ was calculated from the serum L-[tyrosyl-¹⁴C] T₄ concentration and the known volume of distribution of T₄. As shown in Table III, the $[T_4]$ values derived by this method

 TABLE II

 T₃ Radioactivities on the Paper Chromatograms in the Sera and in the Body, [T₃], at Time t

			Ta ra	adioactivi	ties
Subject	Experi- ment	Time	Chromato- grams	Sera	Total pool [T ₁]
		day	dpm Ts area ⁻¹	dpm ml ⁻¹	dpm × 105
J. McD.	1	16.0	31.8	14.4	6.404
	2	20.0	52.8	12.3	5.487
	3	20,5	30.5	7.1	3.168
	4	21.0	49.7	11.6	5.162
	5	21.5	27.3	6.4	2.835
	6	22.0	28.0	6.5	2,910
в. н.	1	8.0	31.3	13.2	5.027
	2	16.0	84.4	19.3	7.334
	3	16.5	64.2	14.7	5.586
	4	17.0	125.4	28.7	10.906
	5	17.5	50.4	11.5	4.370
	6	18.0	111.2	25.4	9.652
	7	18.5	105.6	24.1	9.158
	8	19.0	101.6	23.2	8.816
	9	20.0	84.0	19.2	7.296
D. V.	1	8.0	53.9	34.8	12.013
	2	16.0	40.5	9.3	3.195
	3	16.5	50.8	11.6	4.005
	4	17.0	33.9	7.8	2.674
	5	17.5	32.5	7.4	2.563
	6	18.0	42.9	9.8	3.384
	7	19.0	21.1	4.8	1.663
	8	20.0	15.6	3.6	1.232
D. D.	1	12.0	108.4	40.3	18,735
	2	17.0	54.7	19.2	8.947
	3	17.5	69.7	23.2	10.807
	4	18.0	104.1	34.7	16.145
	5	18.5	73.9	24.6	11.458
	6	19.0	95.8	32.0	14.857
	7	20.0	79.2	26.4	12.281
D. G.	1	20.0	27.3	8.6	3.694
J. Mu.	1	10.0	55.4	31.2	13.429

9-20 ml of the serum samples were applied to the column for deproteinization. The over-all recovery of T_{1} after chromatographies was 17.2-31.8%. The T_{2} radioactivity in serum (dpm ml⁻¹) = T_{1} radioactivity on paper chromatogram (dpm) + total serum volume used (ml) + per cent of T_{4} recovery × 100. T_{3} radioactivity in the body (dpm) = T_{3} radioactivity in serum (dpm ml⁻¹) × T_{3} volume of distribution (1) × 1,000.

agree with those calculated from equations (2) and (4) in most instances. The other method estimated $[T_4]$ by serially subtracting the urinary and fecal recoveries of ¹⁴C from the total L-[tyrosyl-¹⁴C] T₄ injected. As seen in Table III, because of the unavoidable loss of specimen during any long term collection, this last method vastly overestimates the amount of L-[tyrosyl-¹⁴C] T₄ remaining in the body.

In four of the eight subjects, kinetic studies of both T_4 and T_3 were carried out. The results are shown in Table IV. The results from the T_4 studies showed a mean half-time $(t\frac{1}{2})$ of the disappearance of ¹⁴C from serum, 5.62 ± 1.21 days (mean \pm sD). The mean fractional turnover-rate (K) was $12.93 \pm 2.62\%$ per day.

		-		
Subject	Experi- ment	Method 1	Method 2	Method 3
J. McD.	1	120.8	111.3	188.0
J. meb.	2	84.9	121.6	177.1
	3	81.2	105.5	177.1
	4	77.7	103.3	173.8
	5	74.3	66.9	167.0
	6	71.1	77.6	163.8
В. Н.	1	220.2	275.4	221.7
	2	111.0	186.6	294.5
	3	103.8	154.4	287.9
	4	97.1	231.3	281.4
	5	90.9	142.0	275.1
	6	85.0	175.7	271.1
	7	79.5	155.6	266.1
	8	74.4	140.9	266.1
	9	65.1	132.8	260.7
D. V.	1	193.8	233.6	202.6
	2	75.1	66.2	255.6
	3	68.2	61.5	250.3
	4	61.1	52.9	238.7
	5	57.9	50.5	231.6
	6	53.1	43.1	220.4
	7	44.6	41.5	217.8
	8	37.5	32.8	206.7
D. D.	1	316.3	413.5	535.1
	2	158.2	484.6	429.2
	3	147.6	158.7	428.4
	4	137.7	164.1	423.2
	5	128.5	153.2	419.8
	6	119.9	156.9	415.2
	7	104.4	191.2	407.3
D. G.	1	86.4	183.0	71.5
J. Mu.	1	250.0	266.7	216.2

TABLE IIIEstimated L-[Tyrosyl-14C] T_4 in the Body, $[T_4]$, $DPM \times 10^5$

Estimation of the amount of injected L-[tyrosyl-¹⁴C] T₄ remaining in the body at time t, $[T_4]$, by three different methods. Method 1 used the equations (2) and (4). Method 2 used the serum concentration of L-[tyrosyl-¹⁴C] T₄ and the volume of distribution of T₄. Method 3 used subtraction of the ¹⁴C recovery from excreta from the total amount of L-[tyrosyl-¹⁴C] T₄ injected.

The mean zero time volume of distribution (V_d) was 10.1 \pm 1.8 liters. The average extrathyroidal pool of T_4 was 635.0 \pm 130.0 μ g (total T_4) which resulted in a mean T_4 production rate of 82.4 \pm 25.7 μ g per day.

In the same four subjects the results of the T_3 kinetic study showed a mean half-time of 0.92 ± 0.11 days (mean \pm SD). The average fractional turnoverrate of T_3 was 76.12 \pm 7.16% per day. The average zero time volume of distribution of T_3 was 40.9 \pm 4.8 liters. The mean extrathyroidal pool of T_3 was 74.8 \pm 15.8 μ g.

Lastly, the mean daily production rate of T_3 was 57.4 $\pm 14.7 \ \mu g$.

Sufficient data were available to calculate the extrathyroidal conversion rate of T_4 to T_3 , λ , in six of the subjects. Analyses were carried out in six to nine samples of serum from each subject in the majority of instances. The results of λ calculated by equations (2) and (8) or equations (4) and (9) gave essentially similar results. They were grouped together in Table V. The mean conversion rate from the entire group of six subjects was $4.16 \pm 1.44\%$ of extrathyroidal T₄ pool per day (mean \pm sp), or 33.4 \pm 11.0% of T₄ production per day. In four of the six subjects the amount of T₃ generated by the pathway of extrathyroidal conversion was calculated with each subject's own kinetics of T₄ and T₃. For the remaining two subjects, the amount of T_3 converted from T_4 was calculated with the mean values obtained from the other four subjects. The results showed that $26.1 \pm 9.5 \ \mu g$ of thyroxine was metabolized each day by the pathway of extrathyroidal conversion which gave rise to an average of 21.9 ± 7.9 μg of T₃. The amount of T₃ thus derived constituted an average of $31.0 \pm 14.7\%$ of the total extrathyroidal pool of T₃. More important, it constituted an average of $41.2 \pm 20.9\%$ of the daily production rate of T₃.

DISCUSSION

In the past, in vivo evidence of extrathyroidal conversion of T_4 to T_3 were sought by many studies in animals and in man. Most of these studies employed the technique of administering radiothyroxine in one injection, and then the presence or absence of radioactive T₃ was demonstrated by chromatography. The conclusions of most of these studies were equivocal and controversial (6). This controversy can be explained partly by the kinetics of T₃ itself. As shown by the results of our present study and that reported by other investigators, this hormone has a fractional turnover-rate of 70% per day and a half-time of approximately 1 day (17-20). After multiple injections of L-[tyrosyl-¹⁴C] T₄, the ¹⁴C labeled T₃ constituted only 1.6% of the total serum radioactivity. Therefore, demonstration of the extrathyroidal conversion of T_4 to T_3 amidst the multiple artifacts inherent of chromatographic techniques is fraught with pitfalls. (a) Thyroidal contribution of T_3 , (b) contamination of the T_4 dose by T_3 , (c) incomplete separation of the T_4 and T_3 fractions, and (d) artifactual production of T₃ during chromatography are some of the pitfalls.

The procedures followed in our present study were adopted to overcome these very pitfalls. The radiothyroxines used in the study were labeled with ¹⁴C or ³H rather than with a radioiodine, therefore the thyroidal contribution of T₃ in blood was excluded from our calculation. The L-[tyrosyl-¹⁴C] T₄ doses were chromato-

Patients		ta	к	Vd	Extra- thyroidal pool	Production rate
		day	% day-1	liter	μg	µg day-1
Thyroxine	J. McD.	7.85	8.83	7.5	600.0	53.0
	B. H.	5.19	13.35	12.5	875.0	116.8
	D. V.	3.99	17.35	10.2	663.0	115.0
	D. D.	5.00	13.86	10.0	450.0	62.4
	D. G.	6.30	11.00	10.1*	556.0	61.2
	J. Mu.	5.37	12.91	10.1*	665.0	85.9
	Mean	5.62	12.93	10.1	635.0	82.4
	±sd	1.21	2.62	1.8	130.0	25.7
Triiodo- thyronine	J. McD.	0.86	80.35	44.5	102.4	82.3
,	B. H.	0.98	70.50	38.0	60.8	42.9
	D. V.	1.06	65.48	34.5	56.9	37.3
	D. D.	0.79	88.13	46.5	65.1	57.4
	D. G.	0.92*	76.12*	40.9*	77.7	59.2
	J. Mu.	0.92*	76.12*	40.9*	85.9	65.4
	Mean	0.92	76.12	40.9	74.8	57.4
	±SD	0.11	7.16	4.8	15.8	14.7

 TABLE IV

 Kinetic Studies of T4 and T3 in the Same Subjects

 $t_{\rm t}$, the half-time of the radioactivity disappearance from serum. K, the fractional turnover-rate. $V_d,$ zero time volume of distribution. Each mean of the group is shown with its standard deviation.

* No study was carried out for this subject and the value was not included in the mean.

graphed at the beginning and the end of injection period to determine the exact amounts of contamination by ¹⁴C-labeled T₃ which was a very small correction in the present study since most of the sera were collected 5 days after the last ¹⁴C-T₄ injection. As shown in Fig. 3, when serial blood samples were collected after an injection of $D_{L}-[\alpha,\beta^{-3}H]$ T₄, the ³H activity in the T₃ fraction of blood rose with time suggesting that thc formation of ³H-T₃ was primarily due to metabolie events. If the ³H radioactivity in the T₃ fraction was solely due to contamination of the T₄ dose by T₃, the ³H activity should have cleared at the same rate as

Subjects		% T₄ metab	olized per day	% T: generated per day		
	Experi- ments	Extrathyroidal pool	Production rate	Extrathyroidal pool	Production rate	
J. McD.	6	3.6 ± 0.8	40.8	17.7	22.0	
B. H.	9	4.9 ± 1.9	36.9	59.3	84.0	
D. V.	8	2.5 ± 1.0	14.5	24.5	37.4	
D. D.	7	6.8 ± 1.9	48.8	39.1	44.4	
D. G.	1	2.8	25.3	16.6	21.8	
∫. Mu.	1	4.4	34.4	28.8	37.8	
Mean $\pm s$	D	4.2 ± 1.4	33.4 ± 11.0	31.0 ± 14.7	41.2 ± 20.9	

TABLE V The Extrathyroidal Conversion Rates of T_4 to T_3 (λ)

 λ , the extra thyroidal conversion rate. The results of the first four subjects were calculated from their own kinetic data (Table IV). The results of the last two subjects were calculated from the mean values of the first four subjects listed in Table IV.

 $^{14}C-T_3$ and the $^{3}H/^{14}C$ ratios in the T₃ fraction should not have risen with time. The problems of incomplete separation of T₄ and T₃ fractions and the in vitro conversion of T_4 to T_3 are inherent of column and paper chromatographies. The contributions of these artifacts to our ¹⁴C-T₃ measurements were partly corrected for by the addition of D,L- $\lceil \alpha, \beta^{-3}H \rceil$ T₄ to serum samples in our study. At least part of the 3H radioactivity in the T₃ fraction was the combined result from the D,L- $[\alpha,\beta^{-3}H]$ T₄ that remained in the T₃ fraction and the D,L- $[\alpha,\beta-^{3}H]$ T₃ that was formed artifactually. Therefore, the ³H activity in the T₃ fraction was used to correct for the ¹⁴C radioactivity in the T₃ fraction which was due to the contaminating L-[tyrosyl- 14 C] T₄ and the in vitro production of L-[tyrosyl-14C] T₃. When these corrections were applied, the net ¹⁴C radioactivity in the T_3 fraction was never negative in any sample drawn 48 hr after an injection of radiothyroxin. Our results convincingly showed that the pathway of extrathyroidal conversion of T_4 to T_3 is operative in normal man and they support the recent report of Braverman et al (9).

All our serum samples were analyzed by two-dimensional chromatography at the final stage of study. A solvent of hexane: tertiary amyl alcohol: ammonia was used in developing the chromatograms in both directions because this solvent system is particularly suitable in the separation of T₄, T₃, Tetrac, and triiodothyroacetic acid (21). The metabolism of T₄ to Tetrac was observed in animals by many observers before (22-24) and was also observed by Braverman et al. in man (9). Our results agreed with the last report and showed that in a state of near isotopic equilibrium, 14C-labeled Tetrac was found in equal or slightly larger amounts than ¹⁴C-labeled T₃. Since the clearance rate of Tetrac was reported to be slower than that of T_3 by some early studies, the higher serum concentrations of ¹⁴C-labeled Tetrac could not be interpreted to mean a higher production rate for Tetrac than for T₃ in man (25). Recently, Pittman, Read, Chambers, and Nakafuji (13) administered a mixture of D,L- $[a,\beta-^{3}H]$ T₄ and another T₄-labeled with ¹⁴C in the phenolic ring to normal subjects. Approximately 50-60% of the radioactivity was eventually recovered from urine after 3 wk. The ³H/¹⁴C ratios of the urine were the same as the ³H/¹⁴C ratios of the T₄ dose suggesting that the deiodinated metabolites of T4 retained an intact diphenyl ether structure. Therefore, most likely the T₃ and Tetrac formed from T₄ metabolism are in turn deiodinated before urinary excretion without undergoing cleavage of the diphenyl ether.

Detailed study of the T_4 and T_3 kinetics were carried out in the same individual in four of our subjects. Our study of T_4 showed a mean $t\frac{1}{2}$ of 5.62 days, mean turnover-rate of 12.9% per day, mean zero time volume of distribution of 10.1 liter, mean extrathyroidal thyroxine pool 635 μ g (total T₄) and mean daily production 82.4 μ g. Despite the fact that our results were obtained from the mean of only four subjects, these values were essentially in agreement with the results published by Berson and Yalow; Ingbar and Freinkel; and Sterling and Chodos (26, 16, 27). Our mean turnover-rate and production rate of T₄ were slightly higher than the values given in literature which can be explained partly by the fact that our subjects were young and healthy and their values were obtained after approximately 70% of the extrathyroidal T₄ pool was equilibrated with the injected ¹⁴C-T₄.

Our study of T₃ kinetics showed a mean $t\frac{1}{2}$ of 0.92 per day, a mean fractional turnover-rate of 76.1% per day, a mean zero time volume of distribution 40.9 liter, a mean extrathyroidal T₃ pool of 74.8 μ g (total T₃) and a mean production rate of 57.4 μ g. The formation of a ¹³¹I-labeled protein as a degradation product of injected L- $[3'-^{131}I]$ T₃ was reported only recently (17). Comparison of our results with the earlier reports is difficult but our results are in general agreement with the more recent reports of T₃ kinetics by Surks, Woeber, Nicoloff, and Cavalieri and their respective coworkers (17-20). Again, our values of the turnover-rate are slightly higher. Until recently measurements of stable T₃ were not made widely. The absolute production rate or disposal rate of T_3 were not reported by most investigators. Our value of T₃ production rate agreed with that given by Woeber, Sobel, Ingbar, and Sterling 60 μ g per day (18). There are several reported methods for the measurement of stable T₃ in serum employing column and paper chromatographies as well as gas-liquid chromatography (14, 28, 29). The value of T₃ in normal serum by these three methods is well above 200 ng per 100 ml. However, there appeared to be no agreement on the value of stable T_3 in normal serum (30). Apparently no satisfactory correction for chromatographic artifacts as discussed earlier in this paper has been found. The stable serum T₃ in our study was measured by a modified method of Sterling et al. (14) in the Boston Medical Laboratory, Waltham, Mass. Measured by this method the T₃ concentration in normal serum is 150-250 ng per 100 ml which must be taken as an approximation. However, for clinical purposes and in normal subjects this method has been found very reproducible. In the presence of elevated serum T_4 , the measurement of T_3 becomes too high partly due to incomplete separation of the T_4 and T_3 fractions. Braverman et al. (9) reported that their athyreotic patients, whose serum T₄ measurements were elevated to 2-3 times the normal value, were eumetabolic despite serum T₃ measurements in the range of 269-680 ng per 100 ml (9). This discrepancy can be explained partly by the fact that in the presence of excessive T_4 , the T_4 contamination of the T_3 fraction becomes significant in displacement analysis and falsely elevates the T_3 measurements.

The sera studied were collected from our subjects both during and after the injection period of L-[tyrosyl-¹⁴C] T₄. While these different conditions required different methods of calculation, they yielded similar results. Our calculation yielded a mean extrathyroidal conversion rate of T_4 to T_3 , 4.16% of the extrathyroidal T₄ per day. More significantly this pathway was shown to metabolize approximately 33% of the T₄ produced daily. Therefore, approximately 22 μ g of T₃ was generated from the extrathyroidal conversion of T₄. However the contribution of this 22 μ g of T₃ to the over-all production of T₃ is more difficult to assess because of our reservation over the stable T₃ determinations. If these determinations were valid, then extrathyroidal conversion of T_4 to T_3 contributed 41% of the total daily production of T₃.

In conclusion, our study conclusively shows that the pathways of extrathyroidal conversion of T_4 to T_3 and T_4 to Tetrac are operative in normal men. The amount of T_4 metabolized by this pathway accounts for 33% of the total T_4 production and contributes 41% of the total T_3 production each day. Therefore, the extra-thyroidal conversion of T_4 to T_3 is a physiologically important pathway in normal man.

ACKNOWLEDGMENTS

The authors wish to acknowledge the generous help given to us by Dr. Gerald A. Huchison of the Departments of Biomathematics and Engineering Biophysics of the University of Alabama in Birmingham.

This investigation was supported by Grants AM 018181, T1 AM 5058, and 2 M01-Fr 32 from the National Institutes of Health, Bethesda, Md.

REFERENCES

- 1. Gross, J., and R. Pitt-Rivers. 1952. The identification of of 3:5:3'-L-triiodothyronine in human plasma. *Lancet.* 1: 439.
- Taurog, A., J. C. Porter, and D. T. Thio. 1964. Nature of the ¹³¹I-compounds released into the thyroid veins of rabbits, dogs and cats, before and after TSH administration. *Endocrinology*. 74: 902.
- 3. Inoue, K., Y. Grimm, and M. A. Greer. 1967. Quantitative studies on the iodinated components secreted by the rat thyroid gland as determined by *in situ* perfusion. *Endocrinology*. 81: 946.
- Pitt-Rivers, R., J. B. Stanbury, and B. Rapp. 1955. Conversion of thyroxine to 3:5:3'-triiodothyronine in vivo. J. Clin. Endocrinol. Metab. 15: 616.
- 5. Lassiter, W. E., and J. B. Stanbury. 1958. The *in vivo* conversion of thyroxine to 3:5:3'-triiodothyronine. J. C¹in. Endocrinol. Metab. 18: 903.

- Volpert, E. M., R. Grinberg, and S. C. Werner. 1964. Metabolism of labeled thyroid hormone by thyrotropic and adrenotropic mouse pituitary tumors. *Acta. Int. Contra. Cancrum.* 20: 1137.
- Albright, E. C., F. C. Larson, and R. H. Tust. 1954. In vitro conversion of thyroxine to triiodothyronine by kidney slices. Proc. Soc. Exp. Biol. Med. 86: 137.
- 8. Stanbury, J. B. 1960. Deiodination of the iodinated amino acids. Ann. N. Y. Acad. Sci. 86: 417.
- Braverman, L. E., S. H. Ingbar, and K. Sterling. 1970. Conversion of thyroxine (T₄) to triiodothyronine (T₃) in athyreotic human subjects. J. Clin. Invest. 49: 855.
- Pittman, C. S., H. Nakafuji, and V. H. Read. 1970. The metabolites of ¹⁴C labeled thyroxine (T₄) in the blood of normal man. *Clin. Res.* 18: 75.
- Shiba, T., and H. J. Cahnmann. 1962. Synthesis of specifically iodine-¹³¹- and carbon-¹⁴-labeled thyroxine. J. Org. Chem. 27: 1773.
- Nunez, J., C. Jacquemin, and J. Roche. 1962. Preparation de phenols trities, II. J. Appl. Radiat. Isotop. 13: 611.
- Pittman, C. S., V. H. Read, J. B. Chambers, Jr., and H. Nakafuji. 1970. The integrity of the ether linkage during thyroxine metabolism in man. J. Clin. Invest. 49: 373.
- Sterling, K., D. Bellabarba, E. S. Newman, and M. A. Brenner. 1969. Determination of triiodothyronine concentration in human serum. J. Clin. Invest. 48: 1150.
- 15. Murphy, B. E. P., and C. J. Pattee. 1964. Determination of thyroxine utilizing the property of protein-binding. J. Clin. Endocrinol. Metab. 24: 187.
- Ingbar, S. H., and N. Freinkel. 1955. Simultaneous estimation of rates of thyroxine degradation and thyroid hormone synthesis. J. Clin. Invest. 34: 808.
- Surks, M. I., and J. H. Oppenheimer. 1969. Formation of iodoprotein during the peripheral metabolism of 3,5,3'triiodo-L-thyronine-¹²⁵I in the euthyroid man and rat. J. Clin. Invest. 48: 685.
- Woeber, K. A., R. J. Sobel, S. H. Ingbar, and K. Sterling. 1970. The peripheral metabolism of triiodothyronine in normal subjects and in patients with hyperthyroidism. J. Clin. Invest. 49: 643.
- Nicoloff, J. T., and J. Low. 1970. Triiodothyronine (¹²⁵I T₃) and thyroxine (¹³¹I T₄) kinetics in man. Program of the 52nd Annual Meeting of the Endocrine Society, St. Louis, Mo. 93.
- Cavalieri, R. R., M. Steinberg, and G. L. Searle. 1970. Metabolism of T₃ in Graves' disease. Program of the 6th International Thyroid Conference, Vienna, Austria. 48.
- Bellabarba, D., R. E. Peterson, and K. Sterling. 1968. An improved method for chromatography of iodothyronines. J. Clin. Endocrinol. Metab. 28: 305.
- 22. Roche, J., R. Michel, and J. Tata. 1954. Sur le nature des combinaisons iodées excrétées par le foie et le rein après administration de L-thyroxine et de L-3:5:3'-triiodothyronine. *Biochim. Biophys. Acta.* 15: 500.
- 23. Albright, E. C., F. C. Larson, K. Tomita, and H. A. Lardy. 1956. Enzymatic conversion of thyroxine and triiodothyronine to the corresponding acetic acid analogues. *Endocrinology*. 59: 252.
- 24. Galton, V. A., and R. Pitt-Rivers. 1959. The identification of the acetic acid analogues of thyroxine and triiodothyronine in mammalian tissues. *Biochem. J.* 72: 319.
- 25. Green, W. L., and S. H. Ingbar. 1961. The peripheral

Thuroxine Metabolism in Man 1195

metabolism of tri- and tetraiodothyroacetic acids in man. J. Clin. Endocrinol. Metab. 21: 1548.

- 26. Berson, S. A., and R. S. Yalow. 1954. Quantitative aspects of iodone metabolism. The exchangeable organic iodine pool, and the rates of thyroidal secretion, peripheral degradation, and fecal excretion of endogenously synthesized organically bound iodine. J. Clin. Invest. 33: 1533.
- Sterling, K., and R. B. Chodos. 1956. Radiothyroxine turnover studies in myxedema, thyrotoxicosis, and hypermetabolism without endocrine disease. J. Clin. Invest. 35: 806.
- Nauman, J. A., A. Nauman, and S. C. Werner. 1967. Total and free triodothyronine in human serum. J. Clin. Invest. 46: 1346.
- 29. Hollander, C. S. 1968. On the nature of the circulating thyroid hormone: Clinical studies of triiodothyronine and thyroxine in serum using gas chromatographic methods. *Trans. Ass. Amer. Physicians Philadelphia.* 81: 76.
- 30. Bellabarba, D., and K. Sterling. 1969. Formation of Esters of thyroxine and triiodothyronine during alcoholic extraction. J. Clin. Endocrinol. Metab. 29: 1510.